FDA Grants Orphan Drug Status For Personalized Cancer Vaccine, BiovaxID(R), Targeting Mantle Cell Lymphoma
Links shared publicly online about this topic.
- 989total visits
FDA Grants Orphan Drug Status For Personalized Cancer Vaccine, BiovaxID(R), Targeting Mantle Cell Lymphoma
Biovest International, Inc. (OTCQB: BVTI) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, f
View full resource at medicalnewstoday.com
Tags: Vaccination, Cancer, Lymphoma, Non-Hodgkin Lymphoma, Drug, FDA, Vaccine
Most Recently Shared on July 28, 2010 at 3:06 pm By:
FDA Grants Orphan Drug Status For Personalized Cancer Vaccine, BiovaxID(R), Targeting Mantle Cell Lymphoma http://mnt.to/3GF7 #cancer
Also Shared By:
Advertisement
MNT Leukemia
@mnt_leukemia
FDA Grants Orphan Drug Status For Personalized Cancer Vaccine, BiovaxID(R), Targeting Mantle Cell Lymphoma http://mnt.to/3GF7
1 year ago...